Your browser doesn't support javascript.
loading
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study.
Veverka, Karen A; Thng, Steven T G; Silverberg, Jonathan I; Armstrong, April W; Menezes, Josemund; Kaoukhov, Alexandre; Blauvelt, Andrew.
Afiliação
  • Veverka KA; ASLAN Pharmaceuticals, San Mateo, California and Singapore.
  • Thng STG; Skin Research Institute of Singapore, Agency for Science, Technology and Research, National Skin Center, Singapore.
  • Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
  • Armstrong AW; Division of Dermatology, University of California, Los Angeles, Los Angeles, California.
  • Menezes J; ASLAN Pharmaceuticals, San Mateo, California and Singapore.
  • Kaoukhov A; ASLAN Pharmaceuticals, San Mateo, California and Singapore.
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.
J Am Acad Dermatol ; 90(3): 504-511, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37866456
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Eczema Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Eczema Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article